

FCF Fox Corporate Finance | FCF Healthcare & Life Sciences  
**Biotech Venture Capital Monitor – USA**

*August 2023*

*Antibody*



THE FINANCING SPECIALIST

**FCF HEALTHCARE & LIFE SCIENCES  
OVERVIEW**



## Overview



### Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



### Focus Areas

FCF advises on the following transaction types:



**FCF Healthcare & Life Sciences**  
*advises leading HC & LS companies in Europe in financing transactions*

*Over EUR 2bn Healthcare & Life Sciences transaction volume*  
*(Professionals and Advisors)*

*Healthcare & Life Sciences Team of >12*

*Over 100 years in aggregated Healthcare & Life Sciences experience*

*Access to > 1,500 international investors*

**Company Valuation**  
*in partnership with BioScience Valuation GmbH*

**China Licensing**  
*in partnership with YAFO Capital*

**Leading EIB advisor in Europe**

*Over 80 completed Healthcare & Life Sciences transactions (Professionals and Advisors)*

*8 regularly published Healthcare & Life Sciences reports*

## Healthcare & Life Sciences Team



**Dr. Alexandra Goll**  
 Advisor – Venture Capital



**Dr. Axel Polack**  
 Advisor – Science & Technology



**Claus Schalper**  
 Advisor – Corporate Affairs



**Mathias Klozenbuecher**  
 Head of Healthcare & Life Sciences



**Johannes Link**  
 Healthcare & Life Sciences Banking – Europe



**Marco Vollnhals**  
 Healthcare & Life Sciences Banking – Europe



**Enno Spillner**  
 Advisor – Capital Markets



**Dr. Joachim M. Greuel**  
 Advisor – Valuations



**Prof. Dr. Horst Domdey**  
 Advisor – Science & Technology



**Zaid Maleh**  
 Healthcare & Life Sciences Banking – Dubai



**Sean Jian, CFA**  
 Healthcare & Life Sciences Banking – China



## Services

- ✓ Integrated Financial Modelling
- ✓ Investor Screening
- ✓ Management Presentation
- ✓ Post-Transaction Support
- ✓ Due Diligence Support
- ✓ Financing Strategy Advisory
- ✓ Investor / IR Roadshow
- ✓ Equity & Debt Fundraising
- ✓ Term Sheet Negotiation
- ✓ Life Science Advisory Board
- ✓ Closing Assistance
- ✓ IPO Execution Support

*(extract from service portfolio)*



## Our capital markets research feeds our proprietary investor database

### Data Collection

#### Healthcare & Life Sciences

##### Venture Capital Monitor – EU



- Venture Capital
- Healthcare & Life Sciences
- Focus on Europe

##### Healthcare & Life Sciences Venture Capital Report



- Venture Capital
- Healthcare & Life Sciences
- Focus on Europe and the US

##### Biotech Public Equity Monitor



- Public Equity
- Biotech
- Focus on Europe

##### Healthcare & Life Sciences IPO Report



- IPOs
- Healthcare & Life Sciences
- Focus on Europe and the US

##### Biotech Venture Capital Monitor – US



- Venture Capital
- Life Sciences
- Focus on the US

##### Biotech Licensing Monitor – China



- Licensing
- Biotech
- Focus on Europe and Chinese licensors

##### MedTech Public Equity Monitor



- Public Equity
- MedTech
- Focus on Europe

##### Healthcare & Life Sciences SPAC Monitor




- SPACs
- Life Sciences
- Focus on US / Europe and US SPACs

### Market Monitoring


#### Data Processing

- Transaction data
- Investment preferences



#### Proprietary Investor Database

- Most comprehensive database
- > 1,300,000 data points



#### Constant Data Enrichment

- Ongoing investor communication
- Data validation



#### Data-driven Investor Selection

- Intelligent search algorithms
- Big data sequencing

# Executive Summary

*The Biotech Venture Capital Monitor – USA is a monthly published overview focusing on the venture capital financing environment in the US-Biotech segment, and can be used as a quick reference for investors, corporates and professionals*

*More advanced, detailed and / or customized reports are available upon request*

## The Biotech Venture Capital Monitor – USA

is a monthly published overview of Biotech companies, displaying venture capital financing trends in the US-Biotech industry

### Scope

The selection of companies is based on the following criteria:

- Focus on transactions with US-based Biotech companies and available deal volume
- Companies operating in the Biotech sector
- The Biotech sector is further divided into the following indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

*To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information*

## Recipients

The Biotech Venture Capital Monitor – USA targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

## Availability

The Biotech Venture Capital Monitor – USA is available on FCF's website at "<https://www.fcf.de/life-sciences/>"


## Data

All input data is provided by Pitchbook and is not independently verified by FCF. Ratio and multiple calculations are driven based on the input data available. For additional information and disclaimer, please refer to the last page

*If you have questions, comments or ideas, please do not hesitate to contact us*


**BIOTECH VENTURE CAPITAL  
TRANSACTIONS - USA**

AUGUST 2023




### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio	USA	401	D
2	Kriya Therapeutics	USA	362	C
3	Cardurion Pharma	USA	300	A
4	Metagenomi	USA	275	B
5	Orbital Therapeutics	USA	270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering	USA	217	4
2	ARCH Venture Partners	USA	214	15
3	OrbiMed	USA	163	10
4	GV	USA	159	9
5	Alexandria Venture Investments	USA	157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
1	2023-08-30	QSimulate	Other / Undisclosed	Developer of quantitative simulation tools designed to help in quantum molecular simulations in the cloud.	-	1	8	The company raised \$1 million of venture funding on August 30, 2023. The funds will be used to release the world's first covalent inhibitor design system "QuValent" and they aim to expand their business in Japan.
2	2023-08-29	CCM Biosciences	Other / Developing	Operator of a biopharmaceutical company intended to develop drugs for different indications and associated companion diagnostic tests.	A	25	25	The company raised an estimated \$25 million of Series A1 and Series A2 venture funding on August 29, 2023.
3	2023-08-29	Regenerative Medical Solutions	Metabolic Disorders / Pre-clinic	Operator of a biotechnology company intended to provide regenerative medical products to treat diabetes.	-	5	8	The company raised \$5 million of venture funding on August 29, 2023.
4	2023-08-29	XOStem	Metabolic Disorders / Undisclosed	Developer of a stem cell biotechnology platform designed to treat diabetes.	-	< 1	2	The company raised \$587,000 of venture funding on April 13, 2023.
5	2023-08-28	Rebalance Health	Hormonal Disorders / On market	Operator of a health and performance lifestyle company intended to optimize health and fitness.	C	7	22	The company raised \$7.37 million of Series C venture funding on August 28, 2023, putting the company's pre-money valuation at \$24 million.
6	2023-08-28	Cell Microsystems	Other / On market	Developer of biological tools designed for single-cell research.	-	7	20	The company raised \$6.5 million of venture funding on August 28, 2023.
7	2023-08-28	Suono Bio	Gastrointestinal / IND/CTA filed	Developer of therapeutic products designed for the treatment of inflammatory-mediated diseases.	-	< 1	13	The company raised \$500,000 of venture funding in the form of convertible debt on August 28, 2023.
8	2023-08-28	Twister Biotech	Immunology / Developing	Developer of gene therapies intended to treat rare cancers and autoimmune diseases using a proprietary platform.	-	< 1	1	The company raised \$500,000 of venture funding through a combination of equity and debt on August 28, 2023.


Source: PitchBook as of 06-09-2023; FCF Equity Research

Note: All volumes in USDm; financing rounds without deal values are excluded


<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio		401	D
2	Kriya Therapeutics		362	C
3	Cardurion Pharma		300	A
4	Metagenomi		275	B
5	Orbital Therapeutics		270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering		217	4
2	ARCH Venture Partners		214	15
3	OrbiMed		163	10
4	GV		159	9
5	Alexandria Venture Investments		157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
9	2023-08-25	Genesis Therapeutics	Other / Discovery	Developer of a computational platform designed for the discovery of small-molecule drugs.	B	224	327	The company raised \$224.03 million of Series B venture funding on August 25, 2023. The funds will be used to evolve into a clinical-stage company, further invest in its state-of-the-art AI platform, and ambitiously expand its discovery pipeline. Out of the total funding, \$23.9 million was raised in the form of SAFE Notes which was subsequently converted to equity.
10	2023-08-25	EvolutionaryScale	Other / Discovery	Developer of biology artificial intelligence models intended to design therapies.	-	40	40	The company raised \$40 million of venture funding on August 25, 2023, putting the company's pre-money valuation at \$160 million.
11	2023-08-25	Sightstream	Ophthalmology / Pre-clinic	Operator of a biotechnology research company intended to reverse ocular cell death.	-	< 1	3	The company raised \$250,000 of venture funding in the form of SAFE note on August 25, 2023.
12	2023-08-24	ExcepGen	Other / Discovery	Developer of engineering mRNA therapeutics designed to adapt to the cellular state.	-	4	4	The company raised \$4 million of venture funding on August 24, 2023. The funds will be used in company's research and development, as well as advancing its collaborations with other companies.
13	2023-08-23	Cellares	Other / On market	Developer of a cell therapy manufacturing platform intended to make cell therapy widely available and affordable.	C	255	355	The company raised \$255 million of Series C venture funding on August 23, 2023, putting the company's pre-money valuation at \$435 million.
14	2023-08-23	Rapport Therapeutics	Central Nervous System / Phase I	Operator of a biotechnology company intended to transform the treatment of neurological disorders through precision medicine.	B	150	250	The company raised \$150 million of Series B venture funding on August 23, 2023, putting the company's pre-money valuation at \$260 million. The funds will be used to support ongoing clinical programs in seizure and psychiatric disorders and precision neuromedicine discovery platform.
15	2023-08-23	GATC Health	Other / Pre-clinic	Developer of a multi-omic advanced technology platform designed to provide insight into individualized, specific health risks.	-	11	19	The company raised \$10.6 million of venture funding on April 12, 2023.
16	2023-08-22	Cascade Biocatalysts	Other / Developing	Developer of enzyme immobilization kits designed to improve the sustainability and efficiency of existing processes of chemical manufacturing.	-	3	3	The company raised \$2.6 million of venture funding on August 22, 2023. The funds will be used to scale the company's impact from the lab bench to the pilot scale and to support its initial wave of customers.

Source: PitchBook as of 06-09-2023; FCF Equity Research


Note: All volumes in USDm; financing rounds without deal values are excluded

<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)




### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio		401	D
2	Kriya Therapeutics		362	C
3	Cardurion Pharma		300	A
4	Metagenomi		275	B
5	Orbital Therapeutics		270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering		217	4
2	ARCH Venture Partners		214	15
3	OrbiMed		163	10
4	GV		159	9
5	Alexandria Venture Investments		157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
17	2023-08-22	Creative BioTherapeutics	Oncology / Pre-clinic	Operator of a biotech drug discovery company intended to change the way that cancer and viral disease research is conducted.	-	< 1	< 1	The company raised \$150,000 of angel funding on August 22, 2023.
18	2023-08-21	Gladius Therapeutics	Oncology / Undisclosed	Operator of a clinical stage biopharmaceutical company intended to develop therapeutics that disrupt mitochondrial function in the cancer cell.	-	< 1	< 1	The company raised \$300,000 of venture funding in the form of convertible debt, options and warrant on August 21, 2023.
19	2023-08-21	Biophysical Therapeutics	Other / Pre-clinic	Developer of a biology firm intended to design new drugs.	-	< 1	< 1	The company raised \$100,000 of venture funding on June 5, 2023, putting the company's pre-money valuation at \$5 million.
20	2023-08-18	Viome Life Sciences	Other / Undisclosed	Operator of a biotechnology and healthcare company intended to prevent and reverse chronic diseases.	C	54	161	The company raised \$54 million of Series C venture funding on October 31, 2021. The funds will be used to accelerate the development of its mRNA platform for prevention, diagnosis, and therapeutics for chronic disorders, cancers and aging.
21	2023-08-18	Seek Labs	Other / Undisclosed	Operator of a biotechnology company intended to empower humanity by increasing access to virus diagnostics.	B	14	15	The company raised \$13.64 million of Series B venture funding on August 18, 2023.
22	2023-08-18	Astrocyte Pharmaceuticals	Central Nervous System / Phase I	Operator of a drug development company intended to accelerate the recovery and well-being of brain injury patients.	-	6	16	The company raised \$6 million of venture funding on August 18, 2023. The funds will be used to accelerate the clinical development of AST-004, a promising therapeutic candidate aimed at treating a broad array of acute brain injuries including stroke and traumatic brain injury (TBI), and further assess its potential in preclinical models of Alzheimer's disease.
23	2023-08-17	Abcuro	Immunology / Phase II	Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer.	B	155	207	The company raised \$155 million through a combination of Series B and Series B1 venture funding on August 17, 2023, putting the company's pre-money valuation at \$115 million. The funds will be used to support the completion of Phase 2/3 registrational trial of ABC008, a first-in-class anti-KLRG1 antibody for the treatment of inclusion body myositis as well as the continued development of additional clinical programs.
24	2023-08-17	Noveome Biotherapeutics	Other / Phase II	Developer of novel biotherapeutic products designed to treat inflamed or damaged tissues.	E	21	48	The company raised \$20.7 million of Series E venture funding on August 17, 2023. The funds will be used to support the advancement of the Company's clinical stage program investigating its proprietary, cell-free platform biologic, ST266, for the treatment.


Source: PitchBook as of 06-09-2023; FCF Equity Research

Note: All volumes in USDm; financing rounds without deal values are excluded


<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio	USA	401	D
2	Kriya Therapeutics	USA	362	C
3	Cardurion Pharma	USA	300	A
4	Metagenomi	USA	275	B
5	Orbital Therapeutics	USA	270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering	USA	217	4
2	ARCH Venture Partners	USA	214	15
3	OrbiMed	USA	163	10
4	GV	USA	159	9
5	Alexandria Venture Investments	USA	157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
25	2023-08-17	PredxBio	Other / On market	Operator of a computational pathology company intended to analyze whole slide image pathology samples based on spatial analytics.	A	< 1	2	The company raised \$601,322 of Series A1 venture funding on August 17, 2023, putting the company's pre-money valuation at \$12 million.
26	2023-08-17	Savicell	Oncology / Undisclosed	Developer of a liquid immunobiology platform designed for the early detection of disease.	-	< 1	< 1	The company raised \$224,000 of angel funding on August 17, 2023.
27	2023-08-16	Aether (Discovery Tools)	Other / On market	Developer of machine learning technology designed to re-purpose enzymes in order to create a new compound.	A	49	101	The company raised \$49 million of Series A venture funding on August 16, 2023. The funds will be used to scale the company's platform and grow the company's engineering, machine learning, and hardware teams.
28	2023-08-16	Excellos	Oncology / On market	Developer of cell and gene therapy technology designed to facilitate the advancement of cell and gene therapies.	B	5	20	The company raised \$5 million of Series B venture funding on August 16, 2023, putting the company's pre-money valuation at \$10 million.
29	2023-08-14	Radionetics Oncology	Oncology / Discovery	Operator of a biopharmaceutical company intended to help in the treatment of a broad range of oncology indications.	-	30	30	The company raised \$30 million of venture funding on October 18, 2021.
30	2023-08-14	Matterworks (Healthcare Technology Systems)	Other / On market	Developer of an artificial intelligence platform intended to drive the adoption of metabolomics across the life sciences.	Seed	8	14	The company raised an estimated \$7.7 million of Seed 2 funding on August 14, 2023, putting the company's pre-money valuation at \$20 million.
31	2023-08-11	Melt Pharmaceuticals	Other / Phase II	Developer of non-intravenous and non-opioid sedation and analgesia medicines intended for short-duration medical procedures in outpatient and in-office settings.	-	2	13	The company raised \$1.81 million of venture funding on August 11, 2023.
32	2023-08-11	NoVab	Other / Undisclosed	Developer of a biotechnology platform intended to utilize Variable Lymphocyte Receptors to develop effective and superior therapeutic drugs.	-	< 1	< 1	The company raised \$300,000 of venture funding in the form of convertible debt on March 16, 2022.


Source: PitchBook as of 06-09-2023; FCF Equity Research

Note: All volumes in USDm; financing rounds without deal values are excluded


<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio	USA	401	D
2	Kriya Therapeutics	USA	362	C
3	Cardurion Pharma	USA	300	A
4	Metagenomi	USA	275	B
5	Orbital Therapeutics	USA	270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering	USA	217	4
2	ARCH Venture Partners	USA	214	15
3	OrbiMed	USA	163	10
4	GV	USA	159	9
5	Alexandria Venture Investments	USA	157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
33	2023-08-10	Aulos	Oncology / Phase II	Operator of a biotechnology company intended to develop pharmaceutical preparations for the treatment of cancer.	A	20	60	The company raised \$20 million of Series A-1 venture funding on August 10, 2023, putting the company's pre-money valuation at \$55 million. The funds will be used to advance Aulos' lead human monoclonal antibody candidate, AU-007, through its initial Phase 2 clinical study in solid tumor cancers.
34	2023-08-10	Remedy Plan Therapeutics	Oncology / Pre-clinic	Developer of medical drugs intended to halt tumor growth and prevent cancer.	A	19	30	The company raised \$19.07 million through a combination of Series A Prime-1, Series A Prime-2 and Series A Prime venture funding on August 10, 2023, putting the company's pre-money valuation at \$35.93 million.
35	2023-08-10	Dracen Pharmaceuticals	Oncology / Phase I	Developer of cancer treatment medicines intended to directly shrink tumors and remodel the tumor microenvironment.	-	2	59	The company raised \$2.29 million of venture funding in the form of convertible debt on August 10, 2023.
36	2023-08-10	RS BioTherapeutics	Respiratory Diseases / Developing	Developer of therapy system designed to harness the therapeutic power of cannabinoids in the research, development, and commercialization of chronic and acute pulmonary inflammation-based disease medicines.	-	< 1	3	The company raised \$250,000 of venture funding on August 10, 2023.
37	2023-08-09	ADARx Pharmaceuticals	Genetic Disorders / Undisclosed	Operator of a clinical-stage biotechnology company designed to turn cutting-edge science into life-saving therapeutics.	C	200	353	The company raised \$200 million of Series C venture funding on August 9, 2023, putting the company's pre-money valuation at \$640 million. The funds will be used to further advance the company's clinical programs including ADX-324 and ADX-038 and also to support the advancement of a pipeline of innovative mRNA silencing or editing candidates for the treatment of a broad range of diseases.
38	2023-08-09	Alltrna	Oncology / Discovery	Developer of a tRNA platform intended to decipher tRNA biology and pioneer therapeutics to treat diseases.	B	109	122	The company raised \$109 million of Series B venture funding on August 9, 2023. The funds will be used to enable further buildout of company's machine learning-driven platform to unlock the enormous combinatorial power of tRNA sequences and modifications and advance its first drug candidates towards clinical studies.
39	2023-08-09	Fore Bio	Oncology / Phase I	Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomically defined cancer patients.	-	3	82	The company raised \$2.6 million of venture funding in the form of convertible debt from HBM Healthcare Investments on June 9, 2023.
40	2023-08-09	Georgiamune	Oncology / Phase I	Developer of immunotherapies designed to focus on oncology advancements.	A	75	75	The company raised \$75 million of Series A venture funding on August 9, 2023. The funds will be used to initiate a first-in-human, open-label, phase 1/2 dose-escalation with enrichment and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GIM-122 as a single agent in adults with advanced solid malignancies who have failed treatment with a checkpoint inhibitor and also plans to initiate the company's phase 1/2 clinical trial in the second half of 2023 and continue development of its extensive first-in-class pipeline for cancer and autoimmune diseases with high unmet needs.


Source: PitchBook as of 06-09-2023; FCF Equity Research

Note: All volumes in USDm; financing rounds without deal values are excluded


<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio		401	D
2	Kriya Therapeutics		362	C
3	Cardurion Pharma		300	A
4	Metagenomi		275	B
5	Orbital Therapeutics		270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering		217	4
2	ARCH Venture Partners		214	15
3	OrbiMed		163	10
4	GV		159	9
5	Alexandria Venture Investments		157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
41	2023-08-09	Biopharmaceutical Research Company	Other / On market	Operator of specialty pharmaceutical manufacturing and analytical company intended for plant-based therapeutics and hemp testing.	-	< 1	24	The company raised \$676,065 of venture funding on August 9, 2023.
42	2023-08-08	Spinogenix	Central Nervous System / On market	Operator of a biopharmaceutical company intended to restore the brain connections and functions lost in brain injury and neurodegenerative diseases.	B	5	11	The company raised \$5.20 million of Series B venture funding on August 8, 2023, putting the company's pre-money valuation at \$80 million.
43	2023-08-08	Nevakar Injectables	Other / On market	Operator of a pharmaceutical company intended to focus on developing products in injectable and ophthalmic space.	-	5	248	The company raised \$4.6 million of venture funding on August 8, 2023.
44	2023-08-08	Quadrant Biosciences	Other / On market	Operator of a life science company intended to offer molecular diagnostic solutions to health issues.	-	4	42	The company raised \$3.5 million of venture funding in the form of convertible debt on August 8, 2023.
45	2023-08-08	Azora Therapeutics	Immunology / Phase I	Developer of a therapeutic medicine intended to treat serious, debilitating inflammatory diseases.	-	< 1	8	The company raised \$581,449 of venture funding on August 8, 2023.
46	2023-08-07	MBX Biosciences	Metabolic Disorders / Phase I	Operator of a biopharmaceutical company intended to develop therapies for endocrine diseases.	-	150	325	The company raised \$150 million of venture funding on August 7, 2023.
47	2023-08-04	Adela	Oncology / Developing	Developer of healthcare technologies intended to help in tumor detection.	-	28	88	The company raised \$28.03 million of venture funding on August 4, 2023.
48	2023-08-04	Bilayer Therapeutics	Other / Pre-clinic	Operator of a biotechnology company designed for the treatment of chronic constipation and other diseases of the colon.	-	< 1	4	The company raised \$300,000 of venture funding in the form of convertible note on August 4, 2023.


Source: PitchBook as of 06-09-2023; FCF Equity Research

Note: All volumes in USDm; financing rounds without deal values are excluded


<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (USDm)



#### Indications



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	ElevateBio	USA	401	D
2	Kriya Therapeutics	USA	362	C
3	Cardurion Pharma	USA	300	A
4	Metagenomi	USA	275	B
5	Orbital Therapeutics	USA	270	A

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>1</sup>	# of Deals
1	Flagship Pioneering	USA	217	4
2	ARCH Venture Partners	USA	214	15
3	OrbiMed	USA	163	10
4	GV	USA	159	9
5	Alexandria Venture Investments	USA	157	16

#	Date	Company	Vertical - Indication / Stage	Company Description	Series	Deal Volume (USDm)	Total Raised (USDm)	Deal Synopsis
49	2023-08-02	CG Oncology	Oncology / Phase III	Operator of a clinical-stage biopharmaceutical agency intended to develop the next evolution of oncolytic immunotherapy for patients with advanced cancer.	F	105	318	The company raised \$105 million of Series F venture funding on August 2, 2023, putting the company's pre-money valuation at \$520 million. The funds will be used to support the continued advancement of clinical programs in bladder cancer towards FDA approval including BOND-003, a fully enrolled, single-arm in Phase 3.
50	2023-08-02	MarvelBiome	Other / Developing	Developer of a biopharmaceutical technology designed to harness the power of microbes for treating various human diseases.	-	10	15	The company raised \$10 million of venture funding on August 2, 2023.
51	2023-08-02	Luminary Therapeutics	Oncology / Pre-clinic	Developer of cell therapy platform designed for cancer and autoimmune diseases.	-	2	2	The company raised \$2.15 million of venture funding in the form of SAFE NOTES on January 11, 2023.
52	2023-08-02	Cofactor Genomics	Immunology / On market	Developer of a biotechnology platform designed to help in RNA sequencing and expression analysis.	-	1	29	The company raised \$1.17 million of venture funding on August 2, 2023.
53	2023-08-01	Tisento Therapeutics	Other / Phase II	Developer of medicine intended to treat diseases with significant unmet medical needs.	A	81	81	The company raised \$81 million of Series A venture funding on August 1, 2023, putting the company's pre-money valuation at \$35 million. The funds will be used for the development of the Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat in MELAS and other genetic mitochondrial diseases, as well as the advancement of additional assets for serious diseases with unmet need.
54	2023-08-01	Celebration Life Sciences	Cardiovascular / Phase II	Operator of a biotechnology company intended to develop stem-cell based therapies which are highly specialized to treat specific degenerative conditions.	-	< 1	< 1	The company raised \$285,000 of angel funding on June 2, 2021.

Source: PitchBook as of 06-09-2023; FCF Equity Research

Note: All volumes in USDm; financing rounds without deal values are excluded

<sup>1</sup> Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)



# Contact Details & Disclaimer



## FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany  
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299  
info@fcf.de ▪ www.fcf.de

### Arno Fuchs

*Chief Executive Officer*

P: +49 (89) 206 0409-100  
M: +49 (172) 863 6777  
arno.fuchs@fcf.de

### Mathias Klozenbuecher

*Managing Director*

P: +49 (89) 2060 409-123  
M: +49 (174) 301 1846  
mathias.klozenbuecher@fcf.de

### Johannes Link

*Associate*

P: +49 (89) 206 0409-150  
M: +49 (172) 839 5746  
johannes.link@fcf.de

### Marco Vollnhals

*Intern*

P: +49 (89) 206 0409-127  
marco.vollnhals@fcf.de

## DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023



THE FINANCING SPECIALIST